-
1. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers.
Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K.Nat Commun. 2019 Apr 24;10(1):1894. doi: 10.1038/s41467-019-09856-w.PMID: 31019193 Free PMC article.
-
2. Targeting gene expression to specific cells of kidney tubules in vivo, using adenoviral promoter fragments.
Watanabe S, Ogasawara T, Tamura Y, Saito T, Ikeda T, Suzuki N, Shimosawa T, Shibata S, Chung UI, Nangaku M, Uchida S.PLoS One. 2017 Mar 2;12(3):e0168638. doi: 10.1371/journal.pone.0168638. eCollection 2017.
-
3. Patients with SATB2-associated syndrome exhibiting multiple odontomas.
Kikuiri T, Mishima H, Imura H, Suzuki S, Matsuzawa Y, Nakamura T, Fukumoto S, Yoshimura Y, Watanabe S, Kinoshita A, Yamada T, Shindoh M, Sugita Y, Maeda H, Yawaka Y, Mikoya T, Natsume N, Yoshiura KI.Am J Med Genet A. 2018 Dec;176(12):2614-2622. doi: 10.1002/ajmg.a.40670. Epub 2018 Dec 21.
-
4. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.
Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.ESMO Open. 2018 Feb 23;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. eCollection 2018.
-
5. Proteomics Approach Identifies Factors Associated With the Response to Low-Density Lipoprotein Apheresis Therapy in Patients With Steroid-Resistant Nephrotic Syndrome.
Kuribayashi-Okuma E, Shibata S, Arai S, Ota T, Watanabe S, Hisaki H, Okazaki T, Toda T, Uchida S.Ther Apher Dial. 2016 Apr;20(2):174-82. doi: 10.1111/1744-9987.12356. Epub 2016 Jan 14.
-
6. Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia.
Kinoshita Y, Hori M, Taguchi M, Watanabe S, Fukumoto S.J Clin Endocrinol Metab. 2014 Feb;99(2):E363-8. doi: 10.1210/jc.2013-3430. Epub 2013 Dec 2.
-
7. Influence of RNA Strand Rigidity on Polyion Complex Formation with Block Catiomers.
Hayashi K, Chaya H, Fukushima S, Watanabe S, Takemoto H, Osada K, Nishiyama N, Miyata K, Kataoka K.Macromol Rapid Commun. 2016 Mar;37(6):486-93. doi: 10.1002/marc.201500661. Epub 2016 Jan 14.
-
8. Multifunctional polyion complex micelle featuring enhanced stability, targetability, and endosome escapability for systemic siRNA delivery to subcutaneous model of lung cancer.
Kim HJ, Ishii T, Zheng M, Watanabe S, Toh K, Matsumoto Y, Nishiyama N, Miyata K, Kataoka K.Drug Deliv Transl Res. 2014 Feb;4(1):50-60. doi: 10.1007/s13346-013-0175-6.
-
9. Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles.
Pittella F, Cabral H, Maeda Y, Mi P, Watanabe S, Takemoto H, Kim HJ, Nishiyama N, Miyata K, Kataoka K.J Control Release. 2014 Mar 28;178:18-24. doi: 10.1016/j.jconrel.2014.01.008. Epub 2014 Jan 15.
-
10. Biomolecular robotics for chemomechanically driven guest delivery fuelled by intracellular ATP.
Biswas S, Kinbara K, Niwa T, Taguchi H, Ishii N, Watanabe S, Miyata K, Kataoka K, Aida T.Nat Chem. 2013 Jul;5(7):613-20. doi: 10.1038/nchem.1681. Epub 2013 Jun 2.
-
11. Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG.
Suma T, Miyata K, Anraku Y, Watanabe S, Christie RJ, Takemoto H, Shioyama M, Gouda N, Ishii T, Nishiyama N, Kataoka K.ACS Nano. 2012 Aug 28;6(8):6693-705. doi: 10.1021/nn301164a. Epub 2012 Aug 8.
-
12. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles.
Pittella F, Miyata K, Maeda Y, Suma T, Watanabe S, Chen Q, Christie RJ, Osada K, Nishiyama N, Kataoka K.J Control Release. 2012 Aug 10;161(3):868-74. doi: 10.1016/j.jconrel.2012.05.005. Epub 2012 May 11.
-
13. Direct and instantaneous observation of intravenously injected substances using intravital confocal micro-videography.
Matsumoto Y, Nomoto T, Cabral H, Matsumoto Y, Watanabe S, Christie RJ, Miyata K, Oba M, Ogura T, Yamasaki Y, Nishiyama N, Yamasoba T, Kataoka K.Biomed Opt Express. 2010 Oct 21;1(4):1209-1216.
-
14. A family of autosomal dominant hypocalcemia with an activating mutation of calcium-sensing receptor gene.
Chikatsu N, Watanabe S, Takeuchi Y, Muraosa Y, Sasaki S, Oka Y, Fukumoto S, Fujita T.Endocr J. 2003 Feb;50(1):91-6.
-
15. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients.
Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T.J Bone Miner Metab. 2003;21(3):166-71.
-
16. Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice.
Takeuchi Y, Watanabe S, Ishii G, Takeda S, Nakayama K, Fukumoto S, Kaneta Y, Inoue D, Matsumoto T, Harigaya K, Fujita T.J Biol Chem. 2002 Dec 13;277(50):49011-8. Epub 2002 Oct 15.
-
17. [Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism caused by inactivating mutations of calcium-sensing receptor].
Watanabe S, Fukumoto S.Nihon Rinsho. 2002 Feb;60(2):325-30. Review. Japanese.
-
18. Bartter's syndrome and Gitelman's syndrome: Pathogenesis, pathophysiology, and therapy.
Watanabe S, Uchida S.Nihon Rinsho. 2006 Feb;64 Suppl 2:504-7. Review. Japanese.
-
19. Effects of 1-year treatment with fluvastatin or pravastatin on bone.
Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T.Am J Med. 2001 May;110(7):584-7.
-
20. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome.
Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T.Lancet. 2002 Aug 31;360(9334):692-4.
